Zenas Biopharma (ZBIO) PT Lowered to $43 at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ZBIO Hot Sheet
Price: $28.46 +0.28%
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz lowered the price target on Zenas Biopharma (NASDAQ: ZBIO) to $43.00 (from $46.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Siltronic AG (WAF:GR) (SSLLF) PT Raised to EUR123 at UBS
- FSN Ecommerce Ventures (FSNE:IN) PT Raised to INR300 at Goldman Sachs
- DSM-Firmenich AG (DSFIR:NA) PT Raised to EUR75 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Citi, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
